Key facts
- It has raised $1.7M; the latest was Accelerator/Incubator in Nov 2025.
- Notable investors include Tech Incubator Program for Startup, Genaxis (Korea), K-Bio Bridge, Kingsley Ventures, LS Securities — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for TwinPig BioLab
- ·The full record, as it builds
Funding rounds
No funding rounds for TwinPig BioLab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TwinPig BioLab
Operator of a technology-focused bio-venture intended to develop cancer-preventing drugs. The company leverages research collaborations and a focus on anti-cancer drugs to expedite the development of life-saving treatments, enabling healthcare professionals to improve the lives of patients.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 12
- Website
- twinpigbio.com/
- Ownership
- Privately Held (backing)
TwinPig BioLab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TwinPig BioLab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TwinPig BioLab in its N-PORT filings yet. We sweep new filings monthly.